Mabanal, Jerald S.
HRN: 24-88-91 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/24/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
04/24/2024
04/30/2024
IV
210mg
Q8
T/C Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes